Evidence map›Paper›PMID 26745801›Full record

ArticlePloS one2016

Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies.

Zhi Yon Charles Toh, May Thandar Aung-Htut, Gavin Pinniger, Abbie M Adams, Sudarsan Krishnaswarmy, Brenda L Wong, Sue Fletcher, Steve D Wilton

Abstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Targeting, Mutagenesis, and Functional Testing Strategies for Large Collagens.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. EMQN best practice guidelines for genetic testing in dystrophinopathies.European journal of human genetics : EJHG · 2020
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhi Yon Charles TohWestern Australian Neuroscience Research Institute, Perth, Australia.
May Thandar Aung-HtutCentre for Comparative Genomics, Murdoch University, Perth, Australia.
Gavin PinnigerSchool of Anatomy, Physiology and Human Biology, University of Western Australia, Perth, Australia.
Abbie M AdamsWestern Australian Neuroscience Research Institute, Perth, Australia.
Sudarsan KrishnaswarmyUniversity of Western Australia, Perth, Australia.
Brenda L WongDepartment of Paediatrics, Department of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America.
Sue FletcherWestern Australian Neuroscience Research Institute, Perth, Australia.
Steve D WiltonWestern Australian Neuroscience Research Institute, Perth, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Duchenne and Becker muscular dystrophy severity depends upon the nature and location of the DMD gene lesion and generally correlates with the dystrophin open reading frame. However, there are striking exceptions where an in-frame genomic deletion leads to severe pathology or protein-truncating mutations (nonsense or frame-shifting indels) manifest as mild disease. Exceptions to the dystrophin reading frame rule are usually resolved after molecular diagnosis on muscle RNA. We report a moderate/severe Becker muscular dystrophy patient with an in-frame genomic deletion of DMD exon 5. This mutation has been reported by others as resulting in Duchenne or Intermediate muscular dystrophy, and the loss of this in-frame exon in one patient led to multiple splicing events, including omission of exon 6, that disrupts the open reading frame and is consistent with a severe phenotype. The patient described has a deletion of dystrophin exon 5 that does not compromise recognition of exon 6, and although the deletion does not disrupt the reading frame, his clinical presentation is more severe than would be expected for classical Becker muscular dystrophy. We suggest that the dystrophin isoform lacking the actin-binding sequence encoded by exon 5 is compromised, reflected by the phenotype resulting from induction of this dystrophin isoform in mouse muscle in vivo. Hence, exon skipping to address DMD-causing mutations within DMD exon 5 may not yield an isoform that confers marked clinical benefit. Additional studies will be required to determine whether multi-exon skipping strategies could yield more functional dystrophin isoforms, since some BMD patients with larger in-frame deletions in this region have been reported with mild phenotypes.

Indexed as

AnimalsCells, CulturedChildDisease Models, AnimalDystrophinExonsHumansMaleMiceMice, Inbred C57BLMuscular Dystrophy, DuchenneOligonucleotides, AntisensePhenotypeRNARNA SplicingSequence Analysis, RNADystrophinOligonucleotides, AntisenseRNA

Identifiers

PMID26745801
PMCPMC4706350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.